Cargando…

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

PURPOSE: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that mavorixafor favorably modulates immune cell profi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andtbacka, Robert H.I., Wang, Yan, Pierce, Robert H., Campbell, Jean S., Yushak, Melinda, Milhem, Mohammed, Ross, Merrick, Niland, Katie, Arbeit, Robert D., Parasuraman, Sudha, Bickley, Kris, Yeung, Cecilia CS, Aicher, Lauri D., Smythe, Kimberly S., Gan, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010370/ https://www.ncbi.nlm.nih.gov/pubmed/36923305 http://dx.doi.org/10.1158/2767-9764.CRC-22-0090

Ejemplares similares

S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME
por: Badolato, Raffaele, et al.
Publicado: (2023)

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
por: Dale, D. C., et al.
Publicado: (2022)

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014)

P1253: MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRÖM’S MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES
por: Monticelli, H., et al.
Publicado: (2022)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
por: Puzanov, Igor, et al.
Publicado: (2013)

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
por: Andtbacka, Robert HI, et al.
Publicado: (2014)

The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
por: Fricker, Simon, et al.
Publicado: (2012)

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014)

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
por: Harrington, Kevin J, et al.
Publicado: (2016)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
por: Kaufman, Howard L., et al.
Publicado: (2017)

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
por: Andtbacka, Robert HI, et al.
Publicado: (2015)

Campylobacteriosis, Eastern Townships, Québec
por: Michaud, Sophie, et al.
Publicado: (2004)

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy
por: Yeung, Howa, et al.
Publicado: (2023)

An Orally Bioavailable (Mice) Prodrug of Glutathione
por: Crankshaw, Daune L., et al.
Publicado: (2021)

Isolation of Mycobacterium avium from Potable Water in Homes and Institutions of Patients with HIV Infection in Finland and the United States
por: Ristola, Matti, et al.
Publicado: (2015)

Bioavailability of D4 after inhalation and implantation exposure to silicones.
por: Meeks, Robert G
Publicado: (2002)

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
por: Knochelmann, Hannah M., et al.
Publicado: (2022)

The Role of CXCR3 in DSS-Induced Colitis
por: Chami, Belal, et al.
Publicado: (2014)

High-Resolution Melting System to Perform Multilocus Sequence Typing of Campylobacter jejuni
por: Lévesque, Simon, et al.
Publicado: (2011)

Flavonoid Bioavailability and Attempts for Bioavailability Enhancement
por: Thilakarathna, Surangi H., et al.
Publicado: (2013)

Bioavailability of inhaled or ingested PFOA adsorbed to house dust
por: Gustafsson, Åsa, et al.
Publicado: (2022)

Experimental determination of the oral bioavailability and bioaccessibility of lead particles
por: Deshommes, Elise, et al.
Publicado: (2012)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
por: Andtbacka, Robert H.I., et al.
Publicado: (2019)

Bioavailability Improvement Strategies for Icariin and Its Derivates: A Review
por: Szabó, Róbert, et al.
Publicado: (2022)

The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML)
por: Korbecki, Jan, et al.
Publicado: (2023)

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
por: Babiker, Hani M., et al.
Publicado: (2020)

Campylobacteriosis in Urban versus Rural Areas: A Case-Case Study Integrated with Molecular Typing to Validate Risk Factors and to Attribute Sources of Infection
por: Lévesque, Simon, et al.
Publicado: (2013)

RF23 | PSAT259 Comparable Bioavailability of a Novel Levothyroxine Solution when Administered with Coffee
por: Washington, Kris, et al.
Publicado: (2022)

A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine
por: Bi, Ye, et al.
Publicado: (2020)

El clavel verde /
por: Hichens, Robert Smythe, 1864-1950
Publicado: (2003)

Differential role of CXCR3 in inflammation and colorectal cancer
por: Abron, Jessicca D., et al.
Publicado: (2018)

Computer‐aided assessment of the chemokine receptors CXCR3, CXCR4 and CXCR7 expression in gallbladder carcinoma
por: Yu, Xiao, et al.
Publicado: (2020)

Down-regulation of cell surface CXCR4 by HIV-1
por: Choi, Bongkun, et al.
Publicado: (2008)

Effect of food processing on antioxidants, their bioavailability and potential relevance to human health
por: Toydemir, Gamze, et al.
Publicado: (2022)

Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation
por: Suárez-Fariñas, Mayte, et al.
Publicado: (2013)

CXCR7 Controls Competition for Recruitment of β-Arrestin 2 in Cells Expressing Both CXCR4 and CXCR7
por: Coggins, Nathaniel L., et al.
Publicado: (2014)

CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members
por: Guo, Kaibo, et al.
Publicado: (2019)

Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis
por: Weigold, Florian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bqkkbkosj4l8ncft3gtfh2djro